Protalix BioTherapeutics, Inc. (PLX )
Currency in USD Disclaimer
Subscribe Now for Delta3 AI Alerts
Don’t miss out on top stock picks and market insights. Subscribe to Delta3 AI Alerts for real-time updates and expert analysis straight to your inbox. Stay informed and maximize your investment potential.
Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
- Symbol PLX
- Company Protalix BioTherapeutics, Inc.
- Price $1
- Changes Percentage -1.96
- Change -0.02
- Day Low $0.99
- Day High $1.03
- Year High $1.9
- Year Low $0.82
- Market Cap $73,542,700
- Price Avg 50 EMA (D) $1.06
- Price Avg 200 EMA (D) $1.31
- Exchange AMEX
- Volume 68,828
- Average Volume 396,932
- Open $1.02
- Previous Close $1.02
- EPS -0.23
- PE -4.35
- Earnings Announcement 2024-11-04 10:59:00
- Shares Outstanding $73,542,700
Company brief: PROTALIX BIOTHERAPEUTICS, INC. (PLX )
- Healthcare
- Biotechnology
- Mr. Dror Bashan
- https://www.protalix.com
- US
- N/A
- 05-15-1998
- US74365A3095
Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso for the treatment of Gaucher disease. Its product pipeline comprises PRX-102, a therapeutic protein candidate, which is in the last stage of clinical trials for the treatment of Fabry diseases; PRX-110, a proprietary plant cell recombinant form of human deoxyribonuclease I that has completed phase IIa clinical trials for the treatment of cystic fibrosis; PRX-115, a plant cell-expressed recombinant PEGylated Uricase for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate for the treatment of NETs-related diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz (Fiocruz); and Chiesi Farmaceutici S.p.A. The company was founded in 1993 and is based in Hackensack, New Jersey.
PLX Corporation News
Protalix BioTherapeutics Announces Repayment of Outstanding Senior Secured Convertible Promissory Notes
prnewswire.com -- Company is debt-free with no outstanding notes Balance sheet provides sufficient runway for ongoing operations CARMIEL, Israel , Sept. 3, 2024 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE Amer...